INSIGHT-After hep C cure, companies target next big liver disease market
November 09, 2014 at 08:00 AM EST
NEW YORK, Nov 9 (Reuters) - Now that new medicines promise to cure millions of hepatitis C patients in coming years, drugmakers including Gilead Sciences Inc are turning their attention to other liver diseases, with a potential market that could rival the success of statins, which generated more than $30 billion a year in sales at their peak.